阿仑单抗：一种高效药物的罕见严重不良事件。 - Suppr

Alemtuzumab: Rare serious adverse events of a high-efficacy drug.

作者信息

Hartung Hans-Peter, Mares Jan, Barnett Michael H

机构信息

Department of Neurology, UKD and Center for Neurology and Neuropsychiatry, LVR Klinikum, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic.

出版信息

Mult Scler. 2020 May;26(6):737-740. doi: 10.1177/1352458520913277. Epub 2020 Apr 16.

DOI:10.1177/1352458520913277

PMID:32298205

Abstract

摘要

相似文献

Alemtuzumab: Rare serious adverse events of a high-efficacy drug.阿仑单抗：一种高效药物的罕见严重不良事件。

Mult Scler. 2020 May;26(6):737-740. doi: 10.1177/1352458520913277. Epub 2020 Apr 16.

Systemic erythematous lupus after treatment of multiple sclerosis with alemtuzumab.用阿仑单抗治疗多发性硬化症后发生的系统性红斑狼疮。

Mult Scler Relat Disord. 2020 Nov;46:102589. doi: 10.1016/j.msard.2020.102589. Epub 2020 Oct 19.

[The use of music therapy in the treatment of adverse effects in patients with multiple sclerosis treated with alemtuzumab].[音乐疗法在治疗接受阿仑单抗治疗的多发性硬化症患者不良反应中的应用]

Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(7. Vyp. 2):73-76. doi: 10.17116/jnevro202012007273.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" Multiple Sclerosis and Related Disorders 2017.回应：S. 塞加 - 亚兹贝克等人：“多发性硬化症患者中与阿仑单抗相关的输液相关反应的管理” 《多发性硬化症及相关疾病》2017年。

Mult Scler Relat Disord. 2017 Oct;17:177-178. doi: 10.1016/j.msard.2017.08.001. Epub 2017 Aug 9.

Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis - Not always self-limiting, fully reversible or predictable.用于治疗多发性硬化症的阿仑单抗输注时即刻出现的血小板减少症——并非总是自限性、完全可逆或可预测的。

Mult Scler. 2018 Apr;24(4):552-553. doi: 10.1177/1352458517719151. Epub 2017 Jun 29.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.阿仑单抗治疗后改用奥瑞珠单抗的格雷夫斯病缓解。

Acta Neurol Belg. 2022 Aug;122(4):1117-1120. doi: 10.1007/s13760-022-01962-9. Epub 2022 May 19.

Emerging safety issues in alemtuzumab-treated MS patients.阿仑单抗治疗的多发性硬化症患者中出现的安全性问题。

Mult Scler. 2019 Aug;25(9):1206-1208. doi: 10.1177/1352458519851219.

Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).评估在接受阿仑单抗（EMERALD）治疗的复发性缓解型多发性硬化症（RRMS）患者中预防和管理输注相关反应（IARs）的综合输注指导的单臂研究。

Mult Scler Relat Disord. 2019 Apr;29:7-14. doi: 10.1016/j.msard.2019.01.019. Epub 2019 Jan 6.

引用本文的文献

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database.基于FAERS数据库的药物性自身免疫性肝炎真实世界药物警戒研究

Sci Rep. 2025 Feb 8;15(1):4783. doi: 10.1038/s41598-025-89272-x.

Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis.一名多发性硬化症患者使用阿仑单抗后出现全秃和短暂性调节痉挛。

Ther Adv Neurol Disord. 2022 Oct 8;15:17562864221127476. doi: 10.1177/17562864221127476. eCollection 2022.

Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management.单克隆抗体在复发性多发性硬化症治疗中的应用：重点关注妊娠、疫苗接种和风险管理的概述。

Neurotherapeutics. 2022 Apr;19(3):753-773. doi: 10.1007/s13311-022-01224-9. Epub 2022 Apr 4.

Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection.临床和分子特征分析，以建立针对急性肾移植排斥反应的阿仑单抗治疗反应的潜在预测模型。

Clin Pharmacol Ther. 2022 May;111(5):1155-1164. doi: 10.1002/cpt.2566. Epub 2022 Mar 8.

Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report.多发性硬化症序贯免疫重建疗法的机遇与障碍：病例报告

Front Neurol. 2021 Dec 8;12:664596. doi: 10.3389/fneur.2021.664596. eCollection 2021.

A real-world study of alemtuzumab in a cohort of Italian patients.一项在意大利患者队列中开展的阿仑单抗真实世界研究。

Eur J Neurol. 2022 Jan;29(1):257-266. doi: 10.1111/ene.15121. Epub 2021 Oct 5.

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review.《复发缓解型多发性硬化症及其肝损伤的疾病修饰治疗：叙事性综述》。

CNS Drugs. 2021 Aug;35(8):861-880. doi: 10.1007/s40263-021-00842-9. Epub 2021 Jul 28.

Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients.多发性硬化症用阿仑单抗治疗后发生的全身性脱发。两例患者的两年随访。

Int J Environ Res Public Health. 2021 Jul 9;18(14):7338. doi: 10.3390/ijerph18147338.

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review.使用单克隆抗体疗法治疗多发性硬化症：综述

Biologics. 2021 Jun 30;15:255-263. doi: 10.2147/BTT.S267273. eCollection 2021.

Alemtuzumab-associated diffuse alveolar damage - a case report.阿仑单抗相关性弥漫性肺泡损伤-1 例报告。

BMC Neurol. 2020 Sep 23;20(1):357. doi: 10.1186/s12883-020-01934-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Alemtuzumab: Rare serious adverse events of a high-efficacy drug.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献